These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 28752960)

  • 21. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.
    Gao S; Fan YC; Zhao J; Sun FK; Han J; Zhao ZH; Wang K
    Liver Int; 2014 Aug; 34(7):e229-37. PubMed ID: 24112455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
    Hu KQ; Schiff ER; Kowdley KV; Min AD; Shiffman ML; Lee WM; Goodman ZD; Dau LO; Peschell KJ; Fagan EA; Flaherty JF
    J Clin Gastroenterol; 2010 Aug; 44(7):510-6. PubMed ID: 20179614
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relation of ALT and AST levels to the histopathological changes in liver biopsies of patients with chronic hepatitis C genotype 4.
    Khattab H; Fouad A; Hamza M; Mohey MA; El-Akel W; Ghoneim H; Abul-Fotouh A; Esmat G
    Arab J Gastroenterol; 2015 Jun; 16(2):50-3. PubMed ID: 26184441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreased risk of hepatocellular carcinoma in patients with chronic hepatitis C whose serum alanine aminotransferase levels became less than twice the upper limit of normal following interferon therapy.
    Moriyama M; Matsumura H; Aoki H; Shimizu T; Yamagami H; Shioda A; Kaneko M; Goto I; Tanaka N; Arakawa Y
    Liver Int; 2005 Feb; 25(1):85-90. PubMed ID: 15698403
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Viral kinetics during antiviral therapy in patients with chronic hepatitis C and persistently normal ALT levels.
    Kronenberger B; Herrmann E; Micol F; von Wagner M; Zeuzem S
    Hepatology; 2004 Dec; 40(6):1442-9. PubMed ID: 15565603
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updated thresholds for serum alanine aminotransferase level in a large-scale population study composed of 34 346 subjects.
    Wu WC; Wu CY; Wang YJ; Hung HH; Yang HI; Kao WY; Su CW; Wu JC; Chan WL; Lin HC; Lee FY; Lee SD
    Aliment Pharmacol Ther; 2012 Sep; 36(6):560-8. PubMed ID: 22817613
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A noninvasive model to predict liver histology for antiviral therapy decision in chronic hepatitis B with alanine aminotransferase < 2 upper limit of normal.
    Chen S; Huang H; Huang W
    BMC Gastroenterol; 2021 Jan; 21(1):4. PubMed ID: 33407146
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment.
    Mamori S; Suzuki F; Hosaka T; Akuta N; Someya T; Kobayashi M; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Gastroenterol; 2004 Aug; 39(8):776-82. PubMed ID: 15338372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lower liver cancer risk with antiviral therapy in chronic hepatitis B patients with normal to minimally elevated ALT and no cirrhosis.
    Hoang JK; Yang HI; Le A; Nguyen NH; Lin D; Vu VD; Chaung K; Nguyen V; Trinh HN; Li J; Zhang JQ; Chen CJ; Nguyen MH
    Medicine (Baltimore); 2016 Aug; 95(31):e4433. PubMed ID: 27495067
    [TBL] [Abstract][Full Text] [Related]  

  • 31. α-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C.
    Asahina Y; Tsuchiya K; Nishimura T; Muraoka M; Suzuki Y; Tamaki N; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Enomoto N; Nakagawa M; Kakinuma S; Watanabe M; Izumi N
    Hepatology; 2013 Oct; 58(4):1253-62. PubMed ID: 23564522
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between five-year histological outcome and serial changes in serum alanine aminotransferase in patients with biochemical and virological relapse after interferon treatment for chronic hepatitis C.
    Kobayashi M; Ikeda K; Akuta N; Someya T; Suzuki F; Tsubota A; Suzuki Y; Saitoh S; Arase Y; Chayama K; Kumada H
    Intervirology; 2000; 43(3):174-9. PubMed ID: 11044811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
    Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
    J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High predictability of a sustained virological response (87%) in chronic hepatitis C virus genotype 1 infection treatment by combined IL28B genotype analysis and γ-glutamyltransferase/alanine aminotransferase ratio: a retrospective single-center study.
    Amanzada A; Goralczyk AD; Schneider S; Moriconi F; Lindhorst A; Mihm S; Van Thiel DH; Ramadori G
    Digestion; 2012; 86(3):218-27. PubMed ID: 22964578
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The gamma-glutamyl transpeptidase-to-platelet ratio predicts liver fibrosis and cirrhosis in HBeAg-positive chronic HBV infection patients with high HBV DNA and normal or mildly elevated alanine transaminase levels in China.
    Li Q; Li W; Huang Y; Chen L
    J Viral Hepat; 2016 Nov; 23(11):912-919. PubMed ID: 27375134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical characteristics of patients with chronic hepatitis C showing biochemical remission, without hepatitis C virus eradication, as a result of interferon therapy. The Osaka Liver Disease Study Group.
    Kasahara A; Hayashi N; Mochizuki K; Hiramatsu N; Sasaki Y; Kakumu S; Kiyosawa K; Okita K
    J Viral Hepat; 2000 Sep; 7(5):343-51. PubMed ID: 10971822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of different sofosbuvir based treatment regimens on the biochemical profile of chronic hepatitis C genotype 4 patients.
    Elsharkawy A; Eletreby R; Fouad R; Soliman Z; Abdallah M; Negm M; Mohey M; Esmat G
    Expert Rev Gastroenterol Hepatol; 2017 Aug; 11(8):773-778. PubMed ID: 28480808
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B.
    Wong GL; Chan HL; Tse YK; Yip TC; Lam KL; Lui GC; Wong VW
    J Hepatol; 2018 Oct; 69(4):793-802. PubMed ID: 29758335
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Toward the establishment of a prediction system for the personalized treatment of chronic hepatitis C.
    Ochi H; Hayes CN; Abe H; Hayashida Y; Uchiyama T; Kamatani N; Nakamura Y; Chayama K
    J Infect Dis; 2012 Jan; 205(2):204-10. PubMed ID: 22124128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Amantadine-HCL in the treatment of chronic hepatitis C in non-responders to alpha-interferon. Effect on ALT serum levels and viral load].
    Parolin MB; Lacerda MA; Lopes RW
    Arq Gastroenterol; 1999; 36(2):63-7. PubMed ID: 10511883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.